The AVL9 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the AVL9 gene in the human Jurkat T lymphocyte line. This loss-of-function model enables robust investigation of AVL9-dependent processes without clonal selection, providing a heterogeneous yet functionally consistent system for studying cytoskeletal dynamics. AVL9 is a critical adaptor within the WAVE regulatory complex (WRC), which orchestrates actin polymerization at the leading edge of migrating cells. The polyclonal format ensures representative knockout effects while maintaining experimental reproducibility across diverse assay platforms.
Jurkat cells, originally derived from the peripheral blood of an acute T cell leukemia patient, serve as an established model for T cell signaling and leukemic transformation. These immortalized T lymphocytes retain key signaling cascades, including those governing actin remodeling, chemotaxis, and immune synapse formation. Their well-defined response to T cell receptor engagement and chemokine stimulation makes them an ideal host for dissecting the contributions of AVL9 to cell migration and adhesion. The knockout background provides a disease-relevant context for examining aberrant actin regulation in acute T cell leukemia and metastatic progression.
AVL9 functions as an integral subunit of the pentameric WRC, which transduces upstream signals from activated Rac1 GTPase and PIP3 to the Arp2/3 complex, thereby promoting branched actin nucleation. The WRC is composed of WAVE1, Abi1, Nap1, Sra1, and Brk1, and is further modulated by integrin signaling and Abl kinase activity. AVL9 knockout disrupts this assembly, impairing lamellipodia protrusion and cell motility. In Jurkat cells, this pathway also converges on immune synapse dynamics, where actomyosin forces are required for stable T cell?Cantigen-presenting cell interactions, highlighting the gene??s role in both migration and immune recognition.
The AVL9 knockout Jurkat model offers significant translational advantages by recapitulating cytoskeletal defects observed in leukemia. Impaired lamellipodia formation in these cells may reflect the reduced invasive capacity seen in certain leukemia subtypes, while the polyclonal nature mimics genetic variability encountered in patient samples. This system allows systematic dissection of WRC-dependent motility without confounding clonal artifacts, making it suitable for both mechanistic studies and preclinical therapeutic assessment. It also enables correlation of AVL9 status with activation markers, providing insight into how actin reorganization influences leukemic cell behavior.
These polyclonal knockout cells are well-suited for a wide range of applications, including transwell migration assays to quantify chemotaxis, immunofluorescence staining for Arp2/3 and F-actin distribution, and co-immunoprecipitation of WRC components to assess complex integrity. They can be employed in phospho-Rac1 signaling analyses, flow cytometry-based activation panels, and live-cell imaging of lamellipodia dynamics. The model also supports screening of small-molecule inhibitors targeting the WAVE regulatory complex and anti-metastatic compounds. For additional technical information or to inquire about custom cell engineering services, please contact Ascent Research.
